NCT05251831

Comparative Study Efficacy and Safety of of Activated Versus Non-Activated PRP

Evaluation of Activated Platelet Rich Plasma Versus Non-Activated Platelet Rich Plasma in Alopecia Areata

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Al-Azhar University · Academic / Other
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This was comparative prospective study conducted on 40 subjects, diagnosed with alopecia areata of 40 the scalp, carried in a period from February 2020 and March 2021

Detailed description

Alopecia areata is a common recurrent T cell-mediated autoimmune-induced non-scarring hair loss with not fully understood pathogenesis which affects nearly 2% of the general population during lifetime. The course of the disease is unpredictable and currently, no treatment is available for complete cure or prevention. Platelet-rich plasma is an autologous blood-derived product which widely spread in the last decades for the treatment of different dermatological conditions including different hair disorders. The aim of this work was to evaluate the efficacy and safety of activated platelet-rich plasma in comparison to non-activated platelet-rich plasma in the treatment of alopecia areata.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Intradermal injection	Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.

Timeline

• Start date: 2020-02-01
• Primary completion: 2021-02-01
• Completion: 2021-03-30
• First posted: 2022-02-23
• Last updated: 2022-02-23

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study